The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Sep. 05, 2017

Filed:

Mar. 13, 2014
Applicant:

Miragen Therapeutics, Inc., Boulder, CO (US);

Inventors:

Anita G. Seto, Golden, CO (US);

Eva van Rooij, Utretcht, NL;

Kathryn H. Hutnick, Boulder, CO (US);

Christina M. Dalby, Boulder, CO (US);

Thomas G. Hullinger, Boulder, CO (US);

Rusty Montgomery, Boulder, CO (US);

Assignee:

MIRAGEN THERAPEUTICS, INC., Boulder, CO (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07H 21/04 (2006.01); C12N 15/113 (2010.01); A61K 31/713 (2006.01); C07H 21/00 (2006.01);
U.S. Cl.
CPC ...
C12N 15/113 (2013.01); A61K 31/713 (2013.01); C07H 21/00 (2013.01); C12N 2310/113 (2013.01); C12N 2310/315 (2013.01); C12N 2310/321 (2013.01); C12N 2310/322 (2013.01); C12N 2310/3231 (2013.01);
Abstract

The present invention provides oligonucleotides with chemical motifs that are miR-145 inhibitors. The oligonucleotides can be used for the treatment and prevention of a condition by inhibiting the expression or activity of miR-145 in cells of a subject in need thereof. Methods provided include treating or preventing pulmonary arterial hypertension, neointima formation, restenosis or hypertension in a subject in need thereof by administering to the subject an inhibitor of miR-145 expression or activity. Pharmaceutical compositions and kits comprising miR-145 inhibitors are also disclosed.


Find Patent Forward Citations

Loading…